Stopping Ozempic: What Happens to Weight, Appetite and Blood Sugar: What the Studies Recorded

A nurse in a diabetes clinic once described the same conversation arriving three times in one morning: a patient whose insurance had changed, a patient tired of nausea, and a patient who had simply reached a goal and wanted to know if the job was finished. Each asked a version of the question now sitting at the top of search trends: what happens when you stop taking Ozempic?

The question is trending for a concrete reason. As of early 2025, we have unusually clear data on it. The long-term extension of the STEP 1 trial reported how much weight came back a year after semaglutide was withdrawn, the SURMOUNT-4 trial did the same for tirzepatide, and large insurance-database analyses show that a substantial share of people stop these medicines within twelve months. Viral posts have filled the gaps with claims about broken metabolism and instant regain.

The studies tell a calmer, more specific story. Here is what they actually recorded.

What happens when you stop taking Ozempic in the first month

Ozempic is the brand name for semaglutide, a once-weekly injection that mimics GLP-1, a gut hormone released after meals that signals fullness to the brain and helps the pancreas release insulin. Semaglutide was engineered to linger. Its half-life, the time it takes for the amount in the blood to fall by half, is about one week, which is why a single missed injection rarely causes anything dramatic.

That long tail shapes the first month after stopping. During week one, most people notice little. By weeks two and three, blood levels have fallen enough that the two most familiar effects begin to fade: food empties from the stomach faster, and the sense of being satisfied by a small plate weakens. Many people describe the return of what online communities call food noise, the background hum of thoughts about eating that the medicine had quieted. By roughly five weeks, the drug is essentially gone from the body.

Nothing about this resembles withdrawal in the sense the word carries for opioids or alcohol. There is no recognized withdrawal syndrome, no shaking, no sweats. Gastrointestinal side effects such as nausea, constipation or reflux typically improve as the medicine clears rather than worsen. What changes is the physiology the medicine had been holding in a different position: appetite signaling, gastric emptying and, for people with type 2 diabetes, the extra push on insulin release.

The practical point is timing. Because the medicine fades over weeks rather than hours, the first month is when old eating patterns can return before anyone has consciously decided to let them. Trial participants who kept lost weight off after stopping were generally those with a plan already in place for exactly this window.

Why appetite comes back so quickly after semaglutide leaves the body

The return of hunger is not a personal failing, and it is not the medicine having damaged something. It is the underlying biology of body weight reasserting itself.

Semaglutide works in at least two places. In the gut, it slows gastric emptying, so a meal physically stays in the stomach longer and the stretch receptors there keep reporting fullness. In the brain, particularly the hypothalamus and brainstem regions that regulate energy balance, it acts on GLP-1 receptors that reduce the drive to eat and dampen the reward value of food. Both actions depend on the drug being present. Remove it, and both revert.

Layered on top is what researchers call adaptive thermogenesis or metabolic adaptation: after weight loss, the body burns somewhat fewer calories than expected for its new size, and hunger hormones such as ghrelin rise while satiety hormones fall. This happens after weight loss from any method, including diet alone, and was documented long before GLP-1 medicines existed. Semaglutide effectively masked that hunger. Once the mask is off, the person faces the same biological headwind as anyone who has lost a substantial amount of weight.

This explains a pattern many clinicians observe: appetite after stopping can feel stronger than it did before the medicine was ever started. The body is not only back at baseline, it is at baseline plus the compensatory hunger of having lost weight. Understanding this in advance changes how people interpret the experience. It is predictable, it is physiological, and it is the main reason weight regain in the trials followed such a consistent curve.

Ozempic rebound weight gain: what the STEP trials recorded

The most quoted number on Ozempic rebound weight gain comes from the STEP 1 trial extension, published in 2022. STEP 1 was a randomized, placebo-controlled trial of weekly semaglutide in adults with obesity or overweight and at least one weight-related condition, without diabetes. After 68 weeks, participants on semaglutide had lost about 17 percent of their starting weight on average, compared with about 2 percent on placebo.

Then the medicine was withdrawn and a subset was followed for another year with no drug and no structured lifestyle program. By week 120, the semaglutide group had regained roughly two-thirds of what they had lost, leaving them about 5 to 6 percent below their original weight. Improvements in blood pressure, cholesterol and blood sugar had largely reverted toward baseline as well.

A second trial, STEP 4, tested the question differently. Everyone took semaglutide for 20 weeks and lost around 10 percent. Participants were then randomized to continue or switch to placebo. Over the following 48 weeks, those who continued lost a further 8 percent or so, while those switched to placebo regained about 7 percent of body weight, ending close to where a 20-week diet alone might have left them.

Two details matter for reading these numbers honestly. First, the average masks a wide spread; some people regained everything and more, others held most of their loss. Second, the STEP 1 extension deliberately offered no ongoing support, so it likely represents a worst-case scenario rather than what happens with a planned transition. The trials establish that regain is the expected default. They do not establish that it is inevitable for every person.

What changed recently in the evidence on stopping

Three developments since late 2023 explain why this topic feels urgent rather than academic.

In December 2023, JAMA published SURMOUNT-4, the first large withdrawal trial of tirzepatide, the active ingredient in Mounjaro and Zepbound. It is discussed in detail below, but its headline finding, roughly 14 percent of body weight regained over a year after switching to placebo, confirmed that the regain pattern seen with semaglutide is a class effect of GLP-1-based medicines rather than a quirk of one drug.

Through 2024, several observational analyses of United States pharmacy and insurance records tracked how long people actually stay on these medicines outside trials. Estimates vary with the population, but studies have consistently found that a large share of adults without diabetes discontinue within a year, with figures near or above half in some datasets. Cost, side effects and supply shortages were the recurring reasons recorded. That means the question of what happens after stopping is now a mainstream experience, not an edge case.

Regulators also broadened why people take these drugs. In March 2024 the U.S. Food and Drug Administration approved Wegovy, the higher-strength weight-management version of semaglutide, to reduce the risk of heart attack and stroke in adults with cardiovascular disease and obesity or overweight, based on the SELECT trial. In December 2024, Zepbound was approved for moderate to severe obstructive sleep apnea in adults with obesity. When a medicine is prescribed for heart or breathing outcomes rather than the number on a scale, the calculus around stopping shifts, and clinicians increasingly frame these as long-term treatments for a chronic condition.

What the evidence actually says, graded by strength

Not every claim about stopping Ozempic rests on the same foundation. Grading the evidence keeps expectations honest.

Strong evidence from randomized trials. Weight regain after withdrawal is the best-established finding. STEP 1 extension, STEP 4 and SURMOUNT-4 were all randomized, involved hundreds to thousands of participants, and pointed the same direction: substantial regain within a year, with cardiometabolic markers such as blood pressure and HbA1c tracking the weight back up. Randomized trials also firmly establish that semaglutide lowers blood glucose in type 2 diabetes, which implies, logically and observationally, that glucose rises when it is removed.

Moderate evidence from observational data. Discontinuation rates in real-world use, the reasons people stop, and the observation that people who keep exercising and following structured nutrition regain less all come from cohort studies and registries. These are informative but cannot fully separate cause from correlation; people who exercise consistently may differ in other ways.

Weak or absent evidence. Whether gradually reducing the dose before stopping preserves weight better than stopping outright has not been tested in a published randomized trial. The idea that people regain more than they lost as a rule is not supported; trial averages show partial regain. Claims that these medicines permanently alter metabolism in either direction are not supported by trial data, which show the body returning toward its pre-treatment state.

Expert opinion currently fills the gaps, and mainstream bodies such as the NHS describe obesity as a long-term condition requiring ongoing management, with medicines viewed as one component rather than a course to be completed. That framing is a judgment grounded in the trials, not a trial result in itself.

What happens when you stop taking Ozempic if you have type 2 diabetes

Ozempic is approved for type 2 diabetes, and for this group weight is only part of the story. The larger question is glucose.

In the trials that led to its approval, semaglutide lowered HbA1c, the three-month average of blood sugar, by roughly 1 to 1.8 percentage points depending on the comparison. It does this mainly by boosting insulin release when glucose is high, suppressing glucagon (the hormone that tells the liver to release sugar) and slowing how quickly a meal reaches the bloodstream. Each mechanism switches off as the drug clears.

The result is that fasting and after-meal glucose typically climb over the weeks following the last injection, often returning toward pre-treatment levels within one to three months. If weight regain follows, insulin resistance tends to worsen too, adding a second upward push over the subsequent year. The STEP 1 extension recorded this reversal in a non-diabetic population; in people with diabetes the effect on glucose is more consequential.

Two practical realities follow. Many people take semaglutide alongside metformin, insulin or other glucose-lowering medicines that were adjusted downward when semaglutide was added. Removing semaglutide without revisiting the rest of the regimen can leave blood sugar unmanaged. Conversely, some people find their other medicines were reduced or removed while weight came down, and those decisions may need reconsidering.

Both are reasons no one with type 2 diabetes should stop Ozempic on their own. A clinician can arrange more frequent glucose monitoring, decide whether another medicine should be adjusted, and check kidney function and HbA1c at sensible intervals. The medicine’s benefit for glucose control is real and well documented; so is its disappearance when the medicine stops.

Stopping Mounjaro: does tirzepatide behave differently?

People searching about stopping Mounjaro are often hoping for a different answer. The data suggest the pattern is the same, though the numbers differ in ways worth knowing.

Tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for weight management and sleep apnea, activates two gut-hormone receptors rather than one: GLP-1 and GIP, a related hormone that also influences insulin release and fat metabolism. In head-to-head and indirect comparisons, it produces somewhat larger average weight loss than semaglutide, in the range of 20 percent or more of body weight over about 18 months in people without diabetes.

SURMOUNT-4, published in JAMA in December 2023, asked what happens when it is withdrawn. All participants took tirzepatide for 36 weeks and lost around 21 percent on average. They were then randomized to continue or switch to placebo for 52 more weeks. Those who continued lost a further 5 percent or so. Those on placebo regained about 14 percent of body weight. Roughly nine in ten people who continued maintained at least 80 percent of their loss, compared with fewer than one in five on placebo.

Read one way, that is a stark result. Read another, the placebo group still finished about 10 percent below their starting weight after a full year off the drug, a larger residual benefit than the STEP 1 extension recorded, partly because they had started from a deeper loss. The half-life of tirzepatide is about five days, slightly shorter than semaglutide, so appetite may return a little sooner. Otherwise, the biology is the same: the medicine holds appetite down while present, and the body’s weight-regulating systems push back when it leaves.

Semaglutide versus tirzepatide withdrawal: the numbers side by side

Numbers scattered across three trials are easier to compare in one place. The table summarizes what each randomized withdrawal study recorded, with figures rounded and expressed as change in body weight.

Trial	Medicine	Loss before withdrawal	Regained off treatment	Net change from start
STEP 1 extension (2022)	Semaglutide, weekly	About 17% over 68 weeks	About two-thirds of loss over 52 weeks, no lifestyle program	About 5 to 6% below baseline at week 120
STEP 4 (2021)	Semaglutide, weekly	About 10% over 20 weeks	About 7% over 48 weeks on placebo	Near baseline; continued group lost a further 8%
SURMOUNT-4 (2023)	Tirzepatide, weekly	About 21% over 36 weeks	About 14% over 52 weeks on placebo	About 10% below baseline at week 88

Three patterns emerge. First, regain in every trial was substantial but partial; no group returned to above its starting weight on average. Second, the deeper and longer the initial loss, the more weight remained a year later, which argues against stopping early at the first plateau. Third, the trials differ in what they offered after withdrawal. STEP 1 extension offered nothing; STEP 4 and SURMOUNT-4 maintained a lifestyle intervention throughout, which may partly explain why their placebo groups held on to more.

What the table cannot show is individual variation, which was large in every study. Averages describe populations. They are a useful forecast, not a personal destiny.

Has anyone kept the weight off after stopping Ozempic?

Yes, and the trials contain them, even if headlines rarely do. In every withdrawal study a minority of participants maintained most of their loss a year later. In SURMOUNT-4 roughly one in six people on placebo kept at least 80 percent of what they had lost. Observational reports describe similar minorities.

What distinguishes them is not fully understood, but some factors recur across weight-maintenance research generally, not only for GLP-1 medicines. Regular physical activity is the most consistent one. A 2021 Danish randomized trial of liraglutide, an older daily GLP-1 medicine, found that participants who combined the drug with a structured exercise program and then stopped the drug maintained more of their loss a year later than those who had relied on the medicine alone. Higher protein intake, consistent meal structure and self-monitoring of weight appear in maintenance studies across the board.

Duration of treatment may also matter. People who stopped after brief use, before new habits had time to form, seem to regain faster than those who used the medicine for a year or more while deliberately building routines. This is a plausible inference from the trial patterns rather than a proven cause.

The honest summary is that keeping weight off after stopping is possible but is the less common outcome without deliberate effort, and even with effort some regain is typical. People who succeed generally treat the months on medicine as an opportunity to change how they shop, cook, move and sleep, so that when appetite returns it meets a different environment. Anyone considering this route should discuss it with the prescribing clinician first.

Why do so many people quit Ozempic?

If the medicine works, why do observational studies find that a large share of users stop within a year? The recorded reasons cluster into a few groups.

Gastrointestinal side effects lead the list. Nausea, vomiting, diarrhea and constipation affect a substantial proportion of people, especially in the first months and after each dose increase. In the STEP 1 trial, gastrointestinal events were the most common reason for discontinuation, though the overall dropout for side effects was under 10 percent. Outside trials, without the same support, tolerance runs thinner.

Access is the second group. Supply shortages between 2022 and 2024 forced many people off treatment involuntarily, and coverage rules that limit the medicine to specific diagnoses have ended treatment for others. Insurance-database analyses repeatedly identify cost and coverage as the main drivers of discontinuation among people without diabetes.

A third group stops on purpose. Some reach a goal weight and assume the treatment is complete. Some are planning pregnancy; semaglutide is not recommended during pregnancy and current guidance advises stopping about two months beforehand, a decision that must be arranged with a clinician. Others develop a complication such as gallstones or pancreatitis that makes continuing inappropriate. A smaller number experience symptoms such as persistent fatigue, hair thinning associated with rapid weight loss, or low mood, and choose to stop.

These reasons matter because they predict what comes next. Someone who stops for side effects may need a different medicine; someone who stops because of access may benefit from planning around an unwanted gap; someone who stops because they feel finished benefits most from an honest conversation about what the trials show.

Ozempic plateau versus stopping: is a stall a reason to quit?

The Ozempic plateau, the point where weight stops falling despite continued treatment, is one of the most common triggers for people to consider stopping. It is also the point at which the trials suggest stopping is least helpful.

Plateaus are expected. In STEP 1, average weight fell steeply through the first six months, slowed, and largely leveled off around 60 weeks. The medicine had not stopped working. Rather, the body had reached a new balance where reduced intake matched reduced energy expenditure at a lower weight. This is the same shape seen with bariatric surgery and with intensive diet programs, and it reflects physiology, not failure.

Reading a plateau as the medicine wearing off leads to a mistaken conclusion. What the medicine is doing at that point is holding weight at the new level, which is precisely the job that becomes hardest without it. Stopping at the plateau removes the support at the moment it is most needed, and the withdrawal trials show what follows.

Clinicians approach plateaus differently. Some review nutrition and activity, since the appetite-suppressing effect can mask a gradual drift toward higher-calorie choices. Some check for sleep, thyroid or medication issues that affect weight. Some consider whether a dose adjustment or a different medicine is appropriate, decisions that rest entirely with the prescriber. Others simply reframe the goal from continued loss to maintenance and accept the plateau as success.

For most people the plateau represents an achieved benefit, not a stalled one. The evidence argues for talking to the prescribing clinician about how to hold it rather than for abandoning it.

Do you have to take Ozempic forever to keep weight off?

The honest answer is that no one has studied forever, and the framing itself may be the wrong one.

Mainstream guidance from bodies such as the NHS and Mayo Clinic describes obesity and type 2 diabetes as chronic conditions managed over years, in the same category as high blood pressure. No one asks whether they must take a blood-pressure medicine forever; the expectation is that it works while taken and that stopping returns the underlying condition. GLP-1 medicines fit that model. The withdrawal trials are, in effect, the experiment that demonstrates it.

That said, several realistic alternatives to indefinite continuous use exist and are being explored, though none has strong trial support yet. Some clinicians and patients use the medicine for an extended period, then attempt a supervised transition off with intensive lifestyle support, accepting some regain and restarting if needed. Others switch to a different medicine for maintenance. Some trials are testing whether less frequent dosing after weight loss maintains results; those data are not yet mature.

What the evidence does not support is the idea that a short course resets the body permanently. Nor does it support the opposite claim, that stopping guarantees regaining everything. The realistic expectation from the trials is partial regain over a year, more with no plan, less with sustained lifestyle change, and a residual benefit that varies widely.

Whether to continue, pause or stop is a decision that weighs side effects, other health conditions, personal goals and the reason the medicine was prescribed in the first place. It is a decision to make with the clinician who knows that full picture, not one to make from a search result.

What organ is Ozempic hard on? Side effects in perspective

This question surfaces in searches about stopping because people wonder whether they are protecting themselves by quitting. The evidence points to specific, mostly uncommon risks rather than a single organ under strain.

The gastrointestinal tract carries the most common burden: nausea, vomiting, diarrhea, constipation and reflux, generally worst early and often easing over time. Severe or prolonged vomiting can cause dehydration, and dehydration is the main route by which the medicine has been linked to acute kidney injury in case reports. The kidneys themselves are not directly damaged; in fact, trials in people with type 2 diabetes and kidney disease have shown protective effects.

The pancreas is the organ most people mean. Pancreatitis, inflammation of the pancreas, has been reported with GLP-1 medicines. Large trials and meta-analyses have not shown a clear increase over placebo, but the label carries a warning and clinicians take severe abdominal pain seriously.

The gallbladder is a better-supported concern. Gallstones and gallbladder inflammation occur more often, partly because rapid weight loss from any cause raises gallstone risk. Thyroid warnings stem from tumors in rodents at high exposure; no clear human signal has been confirmed, but people with a personal or family history of medullary thyroid cancer are advised against these medicines. Observational data have raised a possible association with a rare optic-nerve condition called NAION; the evidence is early and inconsistent.

Mayo Clinic and MedlinePlus list these in detail. The key is that stopping to protect an organ is reasonable only if a specific problem has arisen, and that is a judgment for the prescribing clinician, not a default assumption.

Common myths about what happens when you stop taking Ozempic

Viral claims about life after Ozempic tend to be more dramatic than the trials. Several deserve a direct correction.

Myth: your metabolism is permanently broken. Weight loss from any method lowers resting energy expenditure somewhat, and hunger hormones rise. This is metabolic adaptation, and it is not unique to GLP-1 medicines. Trial participants who stopped returned toward their pre-treatment state; nothing in the data suggests a lasting metabolic injury.

Myth: you regain more than you lost. Individuals vary, and some do overshoot. Averages in STEP 1 extension, STEP 4 and SURMOUNT-4 all show partial regain, with groups finishing below their starting weight.

Myth: stopping suddenly is dangerous. There is no withdrawal syndrome. The genuine concern is unmanaged blood sugar in type 2 diabetes and unplanned return of appetite, both reasons to involve a clinician rather than reasons to fear the act of stopping itself.

Myth: slowly reducing the dose prevents regain. This is plausible and widely discussed, but no published randomized trial has tested it. Any change in dosing belongs with the prescriber, never with self-adjustment.

Myth: the medicine wrecks your stomach for good. Slowed gastric emptying is the intended effect and reverses as the drug clears. Persistent gastroparesis has been reported but is rare.

Myth: cheaper compounded or online versions are the same thing. Compounded semaglutide and tirzepatide are not approved products, have not been evaluated for safety or effectiveness by regulators, and have been the subject of FDA warnings about dosing errors and contamination. They are not appropriate for self-use.

Each myth contains a grain of real physiology stretched past what the evidence supports. The trials are less frightening and more useful.

When to see a doctor about stopping or continuing Ozempic

Every decision about starting, pausing, switching or stopping Ozempic should be made with the clinician who prescribed it. That is not a formality. The person managing your prescription can review blood sugar, other medicines, kidney function and the original reason for treatment in a way no article can.

Arrange a routine conversation before stopping if any of the following apply: you have type 2 diabetes and take other glucose-lowering medicines, you are planning pregnancy or have become pregnant, you have reached a goal weight and are unsure what comes next, side effects are making you consider quitting, or access to the medicine is about to lapse. A planned transition is consistently better than an abrupt one.

Seek prompt medical attention, whether you are still taking the medicine or have recently stopped, for these red-flag signs:

• Severe, persistent abdominal pain, especially if it spreads to the back or comes with vomiting, which can indicate pancreatitis or gallbladder disease.
• Vomiting or diarrhea that prevents you from keeping fluids down for more than a day, or signs of dehydration such as very dark urine, dizziness or confusion.
• Blood sugar readings that are persistently very high after stopping, or symptoms such as extreme thirst, frequent urination, blurred vision or unexplained weakness.
• Symptoms of low blood sugar, particularly if you also take insulin or a sulfonylurea.
• A lump or swelling in the neck, hoarseness or trouble swallowing.
• Sudden vision loss or a dark shadow in one eye.
• Yellowing of the skin or eyes, or pale stools with dark urine.

Persistent low mood, thoughts of self-harm, or rapid unexplained heartbeat also warrant a prompt call. None of these should wait for a scheduled follow-up.

Frequently asked questions

What happens when you stop taking Ozempic cold turkey?

Nothing acute happens because the medicine clears gradually over about five weeks, and there is no withdrawal syndrome. Over the following weeks appetite returns, food moves through the stomach faster, and in type 2 diabetes blood sugar rises toward pre-treatment levels. The real risks of an abrupt stop are unmanaged glucose and unplanned weight regain, both of which are reasons to involve the prescribing clinician first.

How fast does ozempic rebound weight gain happen?

In randomized trials, regain began within the first month or two after withdrawal and continued steadily for about a year. STEP 1 extension participants regained roughly two-thirds of their loss over 52 weeks; SURMOUNT-4 placebo participants regained about 14 percent of body weight in the same period. Individual speed varies widely with activity, diet structure and how long the medicine was used.

Has anyone kept the weight off after stopping Ozempic?

Yes. In every withdrawal trial a minority held most of their loss a year later; in SURMOUNT-4 about one in six people on placebo kept at least 80 percent of it. Regular exercise, structured meals and longer treatment duration appear in those who succeed, though partial regain remains the more common outcome, and the decision to attempt it belongs with a clinician.

Do you have to take Ozempic forever to keep weight off?

The trials show the medicine holds weight down while taken and that most of the benefit fades within a year of stopping, which is why mainstream guidance frames obesity and type 2 diabetes as chronic conditions managed over the long term. Whether to continue indefinitely, pause with lifestyle support, or switch medicines depends on your health picture and is a decision for the prescribing clinician.

Is stopping Mounjaro different from stopping Ozempic?

The pattern is the same: appetite returns and weight regain follows. Tirzepatide has a slightly shorter half-life of about five days, so effects may fade a little sooner. SURMOUNT-4 recorded about 14 percent regain over a year, yet participants stayed roughly 10 percent below their starting weight, a larger residual benefit partly because their initial loss had been deeper.

What is an Ozempic plateau and does it mean the medicine stopped working?

A plateau is the point where weight levels off despite continued treatment, typically after about a year. It does not mean the medicine has failed; it means the body has reached a new balance that the medicine is now helping to hold. Stopping at that point removes support when it matters most, so plateaus are better discussed with a clinician than treated as an exit signal.

Why do so many people quit Ozempic within a year?

Observational analyses of pharmacy and insurance data identify gastrointestinal side effects, cost and coverage limits, and supply shortages as the leading reasons. Some people also stop deliberately after reaching a goal, before pregnancy, or because of a complication such as gallstones. Each reason points toward a different next step, which is why the conversation with a prescriber matters.

What organ is Ozempic hard on?

The gut bears the most common effects, with nausea and bowel changes. Less common but recognized concerns involve the pancreas, through rare pancreatitis, and the gallbladder, through gallstones linked to rapid weight loss. Kidney injury has been reported mainly from dehydration after severe vomiting. Thyroid warnings come from rodent studies without a confirmed human signal. Stopping to protect an organ is a clinician’s judgment, not a default.

Does blood sugar go back up after stopping Ozempic?

For people with type 2 diabetes, yes. Fasting and post-meal glucose typically rise over the weeks after the last dose and often return toward pre-treatment levels within one to three months, with a further push if weight is regained. Because other diabetes medicines were often adjusted when Ozempic was started, stopping should be coordinated with the prescriber and paired with closer glucose monitoring.

Does gradually reducing the dose prevent regain after stopping?

The idea is plausible, but no published randomized trial has tested it, so the evidence is currently theory and anecdote. Trials only compared continuing the medicine with switching directly to placebo. Any change to dosing or frequency should come from the prescribing clinician; self-adjusting or using unapproved compounded products carries risks that outweigh an unproven benefit.

References

• Semaglutide Injection: MedlinePlus Drug Information
• GLP-1 Agonists: Cleveland Clinic
• Obesity: Treatment: NHS

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.